23rd Sep 2019 12:00
Board Change
Sensyne Health appoints Charles Swingland as Non-Executive Chairman
Oxford, UK; 23 September 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, is pleased to announce that Charles Swingland has been appointed Non-Executive Chairman of the Board, effective immediately. Mr Swingland had previously served as Non-Executive Director and Interim Chairman.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson, Chief Executive Officer | |
Lorimer Headley, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Consilium Strategic Communications | +44 20 3709 5700 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
Related Shares:
SENS.L